The Academy of Managed Care Pharmacy (AMCP) thanks the Food and Drug Administration (FDA) for the opportunity to provide comments in response to the request for suggestions, recommendations and comments relevant to the FDA’s newly established Opioid Policy Steering Committee (OPSC) as published in the Federal Register on September 29, 2017.
The Academy of Managed Care Pharmacy (AMCP) appreciates the opportunity to provide information on the application of value-based contracts (VBCs) for insulin pricing initiatives. The shift in payment models is expanding beyond the delivery of health care services to encompass models of compensation between payers and biopharmaceutical manufacturers.
The Academy of Managed Care Pharmacy (AMCP) thanks the Federal Trade Commission (FTC) for the opportunity to provide comments in response to the request for comments titled “Understanding Competition in U.S. Prescription Drug Markets: Entry and Supply Chain Dynamics” released on October 18, 2017.
The Academy of Managed Care Pharmacy (AMCP) thanks the Department of Health and Human Services (HHS) and the Centers for Medicare and Medicaid Services (CMS) for the opportunity to provide comments in response to the proposed rule Patient Protection and Affordable Care Act; HHS Notice of Benefit and Payment Parameters for 2019 (CMS-9930-P).
The Academy of Managed Care Pharmacy (AMCP) thanks the Department of Health and Human Services (HHS), the Centers for Medicare and Medicaid Services (CMS), and the Center for Medicare and Medicaid Innovation (CMMI) for the opportunity to provide comments in response to the request for information (RFI) titled “Centers for Medicare & Medicaid Services: Innovation Center New Direction” released on September 20, 2017.
The Academy of Managed Care Pharmacy (AMCP) thanks the Food and Drug Administration (FDA) for the opportunity to provide comments in response to the request for information titled “Content of Risk Information in the Major Statement in Prescription Drug Direct-to-Consumer Broadcast Advertisements [Docket No. FDA-2017-N-2936]” as published in the Federal Register on August 21, 2017.
Our organizations view medication-assisted treatment (MAT) as an important component of a multipronged approach to addressing opioid abuse and improving treatment. We applaud efforts to expand access to MAT, such as increasing Drug Addiction Treatment Act (DATA) waivered physician’s prescribing caps and allowing nurse practitioners (NPs) and physician assistants (PAs) to obtain a DATA waiver.